[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Iriyama N, Horikoshi A, Hatta Y, Kobayashi Y, Sawada S, Takeuchi J: Localized, splenic, diffuse large B-cell lymphoma presenting with hypersplenism: risk and benefit of splenectomy. Intern Med; 2010;49(11):1027-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized, splenic, diffuse large B-cell lymphoma presenting with hypersplenism: risk and benefit of splenectomy.
  • Herein we report a case of a localized, massive, diffuse large B-cell splenic lymphoma diagnosed by splenectomy.
  • Enhanced computed tomography scanning showed an irregularly enhanced effect in the spleen suggesting a diffuse splenic tumor.
  • The resected spleen weighed 3,500 g.
  • After the operation, the patient recovered from the pancytopenia and pathology diagnosed diffuse large B-cell lymphoma.
  • Standard CHOP plus rituximab chemotherapy was given.
  • [MeSH-major] Hypersplenism / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Splenectomy / adverse effects. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519821.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Khan F, Vessal S, McKimm E, D'Souza R: Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma. BMJ Case Rep; 2010;2010
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma.
  • A gastrosplenic fistula is a rare complication of gastric and splenic lymphomas which can occur spontaneously or secondary to chemotherapy.
  • We report a case of a spontaneous gastrosplenic fistula secondary to a diffuse splenic large B cell lymphoma in a previously well 43-year-old patient.
  • CT imaging demonstrated the fistula, which was subsequently managed with chemotherapy.
  • [MeSH-major] Fistula / etiology. Fistula / radiography. Gastric Fistula / etiology. Gastric Fistula / radiography. Image Interpretation, Computer-Assisted. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / radiography. Multidetector Computed Tomography. Splenic Diseases / etiology. Splenic Diseases / radiography. Splenic Neoplasms / complications. Splenic Neoplasms / radiography
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cooperative Behavior. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interdisciplinary Communication. Methotrexate / administration & dosage. Patient Care Team. Radiographic Image Enhancement. Rituximab. Spleen / pathology. Spleen / radiography. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Fistulas.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 2002 Aug;95(8):941-2 [12190240.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):287-90 [17098664.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):994-6 [6349784.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2460-7 [6388805.001]
  • [Cites] Saudi Med J. 2007 Dec;28(12):1898-900 [18060225.001]
  • [Cites] Ann Hematol. 2008 Apr;87(4):337-8 [17929016.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):69-70 [18386245.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Jan;101(1):76-8 [19335040.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Mar;101(3):222-3 [19388805.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):e15-7 [19433680.001]
  • [Cites] Abdom Imaging. 2002 Nov-Dec;27(6):728-30 [12395264.001]
  • [Cites] Dis Colon Rectum. 1986 Aug;29(8):521-3 [3755392.001]
  • [Cites] Mayo Clin Proc. 1989 Jul;64(7):776-9 [2770360.001]
  • [Cites] Comput Med Imaging Graph. 1990 Jul-Aug;14(4):273-6 [2383867.001]
  • [Cites] J Clin Gastroenterol. 1991 Aug;13(4):478-81 [1918860.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):587-9 [8674934.001]
  • [Cites] J Thorac Imaging. 1996 Spring;11(2):150-2 [8820024.001]
  • [Cites] Am Surg. 1997 Nov;63(11):1007-10 [9358792.001]
  • [Cites] Gulf J Oncolog. 2008 Jan;(3):64-7 [20084800.001]
  • (PMID = 22791483.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  • [Other-IDs] NLM/ PMC3029570
  •  go-up   go-down


3. Chikatsu N, Kojima H, Suzukawa K, Shinagawa A, Nagasawa T, Ozawa H, Yamashita Y, Mori N: ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol; 2003 Aug;16(8):828-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
  • Pathological features and genomic basis of a rare case of ALK(+), CD30(-), CD20(-) large B-cell lymphoma were analyzed.
  • Physical examination and laboratory tests showed anemia (hemoglobin, 7.5 g/dL), mild hepatosplenomegaly, and immunoglobin G (IgG) lambda-type monoclonal gammopathy (IgG, 2782 mg/dL).
  • The lymphoma spread exclusively in extranodal sites such as bone marrow, liver, spleen, ovary, and muscle.
  • Biopsy specimens obtained from the ovary showed monomorphic proliferation of large immunoblastic cells with basophilic cytoplasm, round-shaped nuclei with a high nuclear to cytoplasmic ratio, and prominent single nucleolus.
  • Immunostaining with anti-anaplastic lymphoma kinase (ALK) antibody, ALK1, showed finely granular cytoplasmic staining pattern.
  • These cells were also positive for epithelial membrane antigen, CD4, CD19, CD38, CD138, cytoplasmic IgG, and lambda chain, but negative for CD30 (Ber-H2), CD56, CD57, and other T- and B-cell markers.
  • Southern blot analyses revealed that Ig heavy and lambda light chain genes, but not T-cell receptor (TCR) beta gene, were clonally rearranged.
  • As 2;17 translocation resulting in the fusion of clathrin heavy chain (CLTC) gene with ALK was previously reported in inflammatory myofibroblastic tumor, we performed reverse transcriptase-polymerase chain reaction and demonstrated that the lymphoma cells contained CLTC-ALK fusion transcript.
  • Under the diagnosis of ALK(+), CD30(-), CD20(-) large B-cell lymphoma, she was treated with conventional combination chemotherapies.
  • However, the lymphoma was primarily chemotherapy resistant, and the patient died 11 months after admission.
  • We consider that this case confirms the existence of ALK(+), CD30(-), CD20(-) large B-cell lymphomas proposed by Delsol et al. (16) and further provides relevant information regarding their clinicopathological features and cytogenetics.
  • [MeSH-major] Clathrin Heavy Chains / genetics. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Oncogene Proteins, Fusion. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12920229.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Oncogene Proteins, Fusion; 114899-12-6 / Clathrin Heavy Chains; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


Advertisement
4. Szotkowski T, Szotkowska R, Pikalova Z, Tichy T, Flodr P, Tichy M, Houserkova D, Benysek V, Zlamalova N, Ruzicka V, Indrak K: Spontaneous splenic rupture in two patients with hematologic malignancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun;151(1):113-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous splenic rupture in two patients with hematologic malignancy.
  • BACKGROUND: Spontaneous splenic rupture (SSR) is a very rare complication described in several hundred patients, mainly as case reports.
  • It is defined as a splenic rupture without antecedent injury.
  • PATIENTS: The first patient was admitted to hospital because of planned chemotherapy for relapsed hairy cell leukemia.
  • The diagnose of hematologic malignancy (diffuse large B-cell lymphoma) was determined subsequently on the basis of histological examination of the spleen.
  • CONCLUSION: It is necessary to consider SSR not only in patients with known diagnosis of malignant disease but in the patients with negative anamnesis, too.
  • [MeSH-major] Leukemia, Hairy Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Splenic Rupture / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690752.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


5. Kanai Y, Matsuda M, Iwanaga T, Hashimoto S, Maeda Y, Kanamaru A, Itagaki N: [Diffuse large B-cell lymphoma presenting with hypoglossal nerve palsy and great occipital neuralgia]. Rinsho Ketsueki; 2009 Feb;50(2):113-5
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse large B-cell lymphoma presenting with hypoglossal nerve palsy and great occipital neuralgia].
  • Soluble IL-2 receptor was elevated and malignant lymphoma was clinically diagnosed.
  • PET-CT demonstrated a single hot spot on the spleen.
  • After radiation therapy to the lesion on the petrous bone, splenectomy was performed.
  • Pathological findings established a diagnosis of diffuse large B-cell lymphoma.
  • After chemotherapy consisting of rituximab and THP-COP, complete remission was achieved.
  • [MeSH-major] Hypoglossal Nerve Diseases / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Neoplasms, Multiple Primary. Neuralgia / etiology. Occipital Bone / innervation. Petrous Bone. Skull Neoplasms / complications
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Combined Modality Therapy. Humans. Male. Receptors, Interleukin-2 / blood. Remission Induction. Splenic Neoplasms / complications. Splenic Neoplasms / diagnosis. Splenic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265306.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-2
  •  go-up   go-down


6. Kang KM, Chung WC, Lee KM, Hur SE, Nah JM, Kim GH, Back JY, Kim SK, Yang JM, Choi HJ: [A case of primary hepatic lymphoma mimicking hepatitis]. Korean J Hepatol; 2005 Sep;11(3):284-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary hepatic lymphoma mimicking hepatitis].
  • We report here on a case of non-Hodgkin's lymphoma in which liver involvement was the predominant clinical manifestation.
  • The abdominal CT scan showed only diffuse hepatosplenomegaly and uneven contrast enhancement of the spleen without any definite mass of the liver and spleen.
  • US-guided aspiration biopsy of liver and the histologic examination confirmed a diagnosis of non-Hodgkin's lymphoma, the diffuse large B cell type.
  • Bone marrow biopsy showed the infiltration of malignant lymphoma cells.
  • PET-CT showed an increased FDG uptake of the liver, spleen and long bones.
  • The patient was treated with combination regimen of cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy.
  • Even in the absence of a mass lesion or lymphadenopathy, primary hepatic or hepatosplenic lymphoma should be considered in differential diagnosis of hepatitis or liver cirrhosis, especially for patients with diffuse hepatosplenomegaly and markedly elevated LDH.
  • [MeSH-major] Hepatitis / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177555.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


7. Hsieh MS, Yeh YC, Chou YH, Lin CW: Intravascular large B cell lymphoma in Taiwan: an Asian variant of non-germinal-center origin. J Formos Med Assoc; 2010 Mar;109(3):185-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B cell lymphoma in Taiwan: an Asian variant of non-germinal-center origin.
  • BACKGROUND/PURPOSE: Intravascular large B cell lymphoma (IVLBCL) is a rare variant of diffuse large B cell lymphoma.
  • Six out of seven patients survived after chemotherapy, but three cases with thrombocytopenia that precluded chemotherapy died within 2 months.
  • The liver, spleen, and bone marrow, but rarely the skin or brain, were involved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Formosan Medical Association & Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20434026.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Friedberg JW, Chengazi V: PET scans in the staging of lymphoma: current status. Oncologist; 2003;8(5):438-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET scans in the staging of lymphoma: current status.
  • Positron emission tomography (PET) is a novel functional imaging technique that provides several inherent advantages over conventional nuclear scintigraphy.
  • Several studies have suggested a role for PET using the positron emitter fluorine-18 in the diagnosis and follow-up of patients with lymphoma.
  • This review summarizes the existing data evaluating the role of 2-fluoro-2-deoxy-D-glucose (FDG)-PET in both the staging and follow-up of patients with lymphoma.
  • Most studies of PET involve patients with either Hodgkin's disease or diffuse large B-cell non-Hodgkin's lymphoma.
  • PET detects more disease sites above and below the diaphragm on staging of lymphoma than gallium scintigraphy and may have particular utility in the evaluation of the spleen.
  • Moreover, persistently positive PET scans during and after chemotherapy appear to have a high sensitivity for predicting subsequent relapse.
  • A negative PET scan at the end of therapy provides very favorable prognostic information.
  • Persistently positive PET scans at the end of therapy warrant close follow-up or additional diagnostic procedures, since some of those patients may remain in prolonged remission.
  • Clearly, additional studies, including prospective blinded trials and cost-effectiveness analyses, are warranted to determine which subsets of patients with lymphoma ultimately will benefit from this modality.
  • [MeSH-major] Lymphoma / radionuclide imaging
  • [MeSH-minor] Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Neoplasm Staging. Predictive Value of Tests. Radiopharmaceuticals. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14530496.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 68
  •  go-up   go-down


9. Tsirigotis P, Economopoulos T, Rontogianni D, Dervenoulas J, Papageorgiou E, Bollas G, Mantzios G, Kalantzis D, Koumarianou A, Raptis S: T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma. Oncology; 2001;61(4):257-64
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
  • OBJECTIVES: Clinical features, response to treatment and survival of T-cell-rich B-cell lymphoma (TCRBCL) patients were compared to those of a similar group of patients with diffuse large B-cell lymphoma (DLBCL).
  • METHODS: Between 1992 and 1999, 10 patients with a diagnosis of TCRBCL were treated in our department.
  • Both groups of patients were treated with the same anthracycline-based chemotherapy.
  • TCRBCL patients responded poorly to combination chemotherapy, since only 3 of them achieved complete remission (33%) compared to 48 (75%) patients with DLBCL.
  • CONCLUSIONS: Although the number of patients in our study is small, it seems that patients with TCRBCL present with advanced disease, respond poorly to chemotherapy and display a short disease-free and overall survival compared to patients with DLBCL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Aged. Antigens, CD / immunology. Antigens, CD20 / immunology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Immunohistochemistry. Liver / pathology. Male. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm Staging. Prednisolone / administration & dosage. Prednisone / administration & dosage. Retrospective Studies. Spleen / immunology. Spleen / pathology. Survival Rate. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11721171.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CEOP protocol 1; MCOP protocol
  •  go-up   go-down


10. Yanagiya N, Takahashi N, Nakae H, Kume M, Chubachi A, Miura I: [Plasma exchange and continuous hemodiafiltration as an initial treatment for diffuse large B-cell lymphoma-associated hemophagocytic syndrome]. Rinsho Ketsueki; 2002 Jan;43(1):35-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma exchange and continuous hemodiafiltration as an initial treatment for diffuse large B-cell lymphoma-associated hemophagocytic syndrome].
  • A diagnosis of diffuse large cell, B-cell type malignant lymphoma, associated with hemophagocytic syndrome (LAHS), was made.
  • CT scan revealed lymphadenopathy in the abdominal cavity and multiple tumors in the spleen.
  • Plasma exchange (PE) and continuous hemodiafiltration (CHDF) enabled the patient to undergo diagnostic procedures, irradiation (total 34 Gy) and chemotherapy.
  • Biopsy specimens revealed infiltration of lymphoma cells into the liver and bone marrow.
  • We measured the blood concentrations of TNF-alpha, IL-6, and IL-8 before and after PE and CHDF by the ELISA method, and found normalization of hypercytokinemia after the procedure.
  • It was suggested that initial treatment with PE and CHDF was effective for control of HPS, enabling us to perform chemotherapy for the lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemodiafiltration / methods. Histiocytosis, Non-Langerhans-Cell / complications. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Plasma Exchange

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11868363.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


11. Yeh YM, Chang KC, Chen YP, Kao LY, Tsai HP, Ho CL, Wang JR, Jones D, Chen TY: Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome. Histopathology; 2010 Dec;57(6):785-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome.
  • AIMS: To describe diffuse large B cell lymphoma (DLBCL) presenting initially in bone marrow, liver and spleen (BLS-type) without lymphadenopathy.
  • Usually presenting with fever and haemophagocytic syndrome suggesting infection and complicating timely diagnosis, bone marrow examination showed patchy and interstitial infiltration of large tumour cells without sinusoidal involvement.
  • All cases had a high Ki-67 index (≥90%), commonly a non-germinal centre/activated B cell immunophenotype and were negative for Epstein-Barr virus and human herpesvirus 6 and 8.
  • High-dose chemotherapy with haematopoietic stem cell transplantation prolonged survival in one patient.
  • CONCLUSIONS: Although it shares with intravascular LBCL a subtle presentation and an aggressive clinical course, this primary BLS large cell lymphoma variant is distinguished by lacking an intravascular component and having different cytogenetic findings.
  • [MeSH-major] Bone Marrow / pathology. Liver / pathology. Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Spleen / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 21166693.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Chandra P, Wen YH, Tuli S, Raphael BG, Amorosi EL, Medeiros LJ, Ibrahim S: Postchemotherapy histiocyte-rich pseudotumor involving the spleen. Am J Clin Pathol; 2009 Sep;132(3):342-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postchemotherapy histiocyte-rich pseudotumor involving the spleen.
  • We report 2 cases of splenic postchemotherapy histiocyte-rich pseudotumor.
  • Each patient had a history of diffuse large B-cell lymphoma, treated with multiagent chemotherapy.
  • Computed tomography scans performed on both patients showed splenic masses.
  • A positron emission tomography scan performed on 1 patient showed increased metabolic activity.
  • The preoperative diagnosis in both patients was recurrent lymphoma, prompting splenectomy.
  • The splenectomy specimens showed multiple, tan-white, firm nodules, up to 3.5 cm in diameter, that were histologically composed of central necrotic B cells (CD20+/CD3-), consistent with necrotic lymphoma, surrounded by numerous lipid-laden (xanthomatous) histiocytes.
  • Clinical staging studies at the time of splenectomy showed no other sites of disease.
  • We conclude that these histologic and immunophenotypic findings represent chemotherapy-induced tumor necrosis with a florid histiocytic reaction mimicking residual viable lymphoma.
  • Others have used descriptive terminology or the term xanthomatous pseudotumor for these lesions that have been only rarely reported in the spleen previously.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Histiocytosis / etiology. Histiocytosis / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Spleen / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687310.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Takaku T, Miyazawa K, Sashida G, Shoji N, Shimamoto T, Yamaguchi N, Ito Y, Nakamura S, Mukai K, Ohyashiki K: Hepatosplenic alphabeta T-cell lymphoma with myelodysplastic syndrome. Int J Hematol; 2005 Aug;82(2):143-7
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic alphabeta T-cell lymphoma with myelodysplastic syndrome.
  • We describe a patient with hepatosplenic 33 T-cell lymphoma who showed pancytopenia and myelodysplasia.
  • This treatment resulted in a transient improvement of the cytopenia and a reduction of spleen size.
  • The pathologic findings for the spleen showed diffuse and disseminated infiltration of medium- to large-sized T-lymphocytes in the splenic red pulp.
  • These cells were immunohistochemically positive for CD3, CD5, CD7, CD8, CD16, CD56,T-cell receptor 33 (TCR33),T-cell intracellular antigen 1, and granzyme B but were negative for CD4, CD30, CD57, and TCR33.
  • These data suggested a diagnosis of hepatosplenic 33 T-cell lymphoma.
  • A Southern blot analysis revealed gene rearrangement of the TCR 3-chain gene but not the immunoglobulin heavy chain gene in the spleen cells.
  • The patient received 8 courses of combination chemotherapy and achieved a partial remission; however, the dysplastic features of the marrow cells persisted after the partial remission was obtained.
  • Additional treatment with allogeneic bone marrow transplantation resulted in a transient complete remission; however, the patient relapsed 11 months later.
  • Because he had experienced no lymphadenopathy and showed dysplastic features in the bone marrow, the diagnosis was highly dependent on the pathologic findings for the resected spleen.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma, T-Cell / pathology. Myelodysplastic Syndromes / pathology. Receptors, Antigen, T-Cell, alpha-beta. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Humans. Male. Spleen / metabolism. Spleen / pathology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 15;102(13):4261-9 [12907441.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2612-9 [2249201.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Leukemia. 2000 Jun;14(6):991-7 [10865963.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):285-96 [11224598.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):459-63 [10716161.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4265-74 [8943863.001]
  • [Cites] Am J Pathol. 1990 Sep;137(3):617-28 [1698028.001]
  • [Cites] Am J Hematol. 2001 Jan;66(1):49-52 [11426493.001]
  • [Cites] Blood. 1990 Jun 1;75(11):2213-9 [2140703.001]
  • [Cites] Intern Med. 2000 Jul;39(7):570-5 [10888214.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e119-22 [12653597.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):1027-32 [10895827.001]
  • (PMID = 16146847.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


14. Yagita M, Tabata R, Konaka Y, Ohno T, Takatsuki K: [Intravascular large B-cell lymphoma associated with hypoalbuminemia and hypoxemia]. Rinsho Ketsueki; 2000 Nov;41(11):1189-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravascular large B-cell lymphoma associated with hypoalbuminemia and hypoxemia].
  • A 67-year-old man was referred to our hospital for treatment of hemophagocytic syndrome.
  • Hypotension, hypoxemia, pleural effusion, severe anasarca, and splenomegaly were noticed at the time of admission.
  • Lymphoma was suspected, but effective chemotherapy could not be performed because of progressive hypoxemia and severe hypoalbuminemia, and the patient died of the disease 2 weeks after admission.
  • Autopsy revealed large lymphoid cells packed within systemic vessels as well as invasion into organs such as the liver, lungs, and spleen.
  • The postmortem diagnosis was intravascular large B-cell lymphoma.
  • Hypoalbuminemia and hypoxemia appear to be important clinical features of intravascular large B-cell lymphoma.
  • [MeSH-major] Anoxia / complications. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Serum Albumin / analysis. Vascular Neoplasms / pathology
  • [MeSH-minor] Aged. Histiocytosis, Non-Langerhans-Cell / pathology. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193438.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Serum Albumin
  •  go-up   go-down


15. Natkunam Y, Stanton TS, Warnke RA, Horning SJ: Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab. Clin Lymphoma; 2001 Dec;2(3):185-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
  • A diagnostic continuum exists between lymphocyte-predominant Hodgkin's disease, T-cell-rich B-cell lymphoma (TCRBCL), and diffuse large B-cell lymphoma.
  • While TCRBCLs are uncommon, their clinical and morphologic presentation can mimic other Hodgkin's and non-Hodgkin's lymphomas from which they must be distinguished for diagnosis and treatment.
  • We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Immunophenotyping. Liver / drug effects. Liver / pathology. Liver / radiography. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local. Remission Induction. Rituximab. Spleen / drug effects. Spleen / pathology. Spleen / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11779297.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


16. Foti R, Fazio P, Lizzio G, Leonardi R: [Angioedema: first manifestation of non-Hodgkin's lymphoma]. Ann Ital Med Int; 2002 Jul-Sep;17(3):185-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioedema: first manifestation of non-Hodgkin's lymphoma].
  • In a 48-year-old male patient a diagnosis of a non-Hodgkin lymphoma was made after two episodes of angioedema.
  • Abdominal ultrasonography and computed tomography showed two solid splenic masses infiltrating the greater curvature of the stomach and a 2 cm aortic lymph node.
  • A diagnosis of anaplastic large-cells lymphoma CD30+, anaplastic lymphoma kinase negative was made.
  • The disappearance of the neoplastic gastric infiltration and the decrease in size of the aortic lymph node and splenic mass were achieved after chemotherapy.
  • [MeSH-major] Angioedema / etiology. Autoimmune Diseases / etiology. Complement C1 Inactivator Proteins / deficiency. Complement C1 Inactivator Proteins / immunology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / immunology. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Proteins / analysis. Prednisone / administration & dosage. Spleen / pathology. Stomach / pathology. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Ital Med Int. 2002 Jul-Sep;17(3):143-5 [12402660.001]
  • (PMID = 12402667.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Complement C1 Inactivator Proteins; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


17. Kartsios C, Kaloyannidis P, Yannaki E, Iordanidis P, Penopoulos V, Sakellari I, Anagnostopoulos A: Spontaneous adrenal haemorrhage as a manifestation of isolated relapse of non-Hodgkin's lymphoma. Acta Haematol; 2003;110(4):197-9
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous adrenal haemorrhage as a manifestation of isolated relapse of non-Hodgkin's lymphoma.
  • We describe a 36-year-old woman diagnosed with diffuse large B cell lymphoma (DLBCL) of bone marrow, liver and spleen presenting in the leukaemic phase.
  • The patient attained complete remission after 'ALL-like' chemotherapy (cyclophosphamide, vincristine, adriamycin, dexamethasone); 22 months later, she developed an isolated central nervous system (CNS) relapse which was successfully managed with a combination of chemotherapy and CNS irradiation.
  • Six months later, she was rehospitalized because of abdominal pain; an MRI revealed a large haemorrhagic mass in the left adrenal.
  • Surgical removal of the lesion confirmed an adrenal relapse of the primary DLBCL.
  • [MeSH-major] Adrenal Gland Diseases / diagnosis. Hemorrhage / diagnosis. Lymphoma, Large B-Cell, Diffuse / complications

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14663165.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Sawada M, Yamada T, Tsurumi H, Moriwaki H: [Nasal NK cell lymphoma with hemophagocytic syndrome developed tumor lysis syndrome after CHOP therapy]. Rinsho Ketsueki; 2002 Nov;43(11):988-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasal NK cell lymphoma with hemophagocytic syndrome developed tumor lysis syndrome after CHOP therapy].
  • A biopsy showed diffuse proliferation of large atypical lymphocytes, which were positive for CD45RO, CD56, MIB-1, and EBER.
  • A diagnosis of nasal NK cell lymphoma with hemophagocytic syndrome (clinical stage IVB) was made.
  • Following CHOP regimen chemotherapy, the tumor transiently reduced in size, but the patient developed multiple organ failure possibly due to tumor lysis syndrome.
  • His general condition was improved by intensive supporting therapy.
  • Despite salvage chemotherapy with a P-IMVP16/CBDCA regimen, the patient died of multiple organ failure due to tumor lysis syndrome.
  • Autopsy revealed diffuse necrosis and fibrosis without proliferation of lymphoma cells in the liver, spleen, bone marrow, and lymph nodes.
  • The poor prognosis of NK/T cell lymphoma might be associated with massive tissue damage with hypercytokinemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Histiocytosis, Non-Langerhans-Cell / etiology. Killer Cells, Natural. Lymphoma, T-Cell / drug therapy. Nose Neoplasms / drug therapy. Prednisone / adverse effects. Tumor Lysis Syndrome / etiology. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12508484.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Kitabayashi K, Hasegawa T, Ueno K, Saito H, Kosaka T, Takashima S, Kurose N, Nojima T: Primary hepatic non-Hodgkin's lymphoma in a patient with chronic hepatitis C: report of a case. Surg Today; 2004;34(4):366-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic non-Hodgkin's lymphoma in a patient with chronic hepatitis C: report of a case.
  • We report a case of primary hepatic non-Hodgkin's lymphoma in a 77-year-old man with chronic hepatitis C.
  • Abdominal computed tomography showed that the tumor was marginally enhanced in the early phase, but no enhancement was seen in the late phase.
  • Under the diagnosis of a liver tumor, thought to be a hepatocellular carcinoma, left lateral segmentectomy was performed.
  • Histological examination confirmed a diagnosis of non-Hodgkin's diffuse large B-cell lymphoma that was positive for L-26 and CD79Alpha, but negative for CD3 and UCHL-1.
  • The surrounding liver tissue showed signs of chronic active hepatitis.
  • Multiple recurrent lesions were found in the liver, spleen, and iliac bones 4 months postoperatively.
  • However, complete remission was achieved after five courses of systemic chemotherapy using pirarubicin, cyclophosphamide, vincristine sulfate, and prednisolone.
  • We review the literature on primary non-Hodgkin's lymphoma arising in the liver infected by HCV.
  • [MeSH-major] Hepatitis C, Chronic / complications. Liver Neoplasms / complications. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15052456.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Dunn P, Kuo TT, Shih LY, Lin TL, Wang PN, Kuo MC, Tang CC: Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan. Acta Haematol; 2004;112(4):203-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan.
  • Twenty-three patients with primary salivary gland lymphoma were diagnosed between 1990 and 2001.
  • The sites of lymphoma involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient.
  • Histologically, 19 patients had lymphomas of mucosa-associated lymphoid tissue (MALT) with myoepithelial sialadenitis in 13, 3 patients had diffuse large cell lymphomas and 1 had follicular lymphoma.
  • Eight of 23 patients (35%) had autoimmune diseases before or after the diagnosis of NHL and all suffered from MALT lymphoma.
  • Four patients with parotid MALT lymphoma had primary or secondary Sjogren's syndrome.
  • All the 6 stage I patients had achieved complete remission (CR) without relapses 17-84 months (median 44 months) after treatment.
  • Excluding a stage IV patient with follicular lymphoma who died at 3.5 months without treatment, CR was achieved in all of the remaining 16 patients.
  • These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy.
  • One patient with MALT lymphoma developed histologic transformation into diffuse large lymphoma during relapse and died of refractory disease.
  • Thus, salivary gland lymphoma proved to be an indolent disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Autoimmune Diseases / complications. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / complications. Male. Middle Aged. Radiotherapy. Remission Induction. Survival Rate. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15564732.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Godt C, Regnery A, Schwarze B, Junker K, Porschen R: A rare cause of ulcerative colitis - diarrhoea and perianal bleeding due to posttransplant lymphoproliferative disorder (PTLD). Z Gastroenterol; 2009 Mar;47(3):283-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had received a bone marrow transplant two years previously for an acute lymphocytic leukaemia of B-cell origin.
  • Further investigations revealed a diffuse infiltration of the liver, spleen, both kidneys and lungs.
  • Histologically, a monomorphic post-transplant lymphoproliferative disorder was diagnosed, the subtype was a high grade diffuse-large cell Non-Hodgkin's lymphoma of B-cell origin.
  • The current therapeutic approach to the subtype of PTLD we saw in this patient is CHOP chemotherapy, comprising the anti-CD 20 antibody rituximab if CD 20-positivity is present.
  • This patient had a fatal course of the disease and died a few days after the first chemotherapy cycle due to severe multiple organ failure.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Colitis, Ulcerative / etiology. Colorectal Neoplasms / diagnosis. Diarrhea / etiology. Gastrointestinal Hemorrhage / etiology. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


22. Ruiz-Hernández G, Scaglione C, Delgado-Bolton RC, Gutiérrez-García A, Madero L, Jiménez-Vicioso A, Carreras-Delgado JL: [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF]. Rev Esp Med Nucl; 2004 Mar-Apr;23(2):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF].
  • Biopsy of the mediastinal mass revealed the presence of diffuse large B-cell non-Hodgkin's lymphoma.
  • Treatment included 4 cycles of chemotherapy followed by 7 days of subcutaneous granulocyte colony-stimulating factor (G-CSF, Lenogastrim) at a dose of 5 mg/Kg/day.
  • Following treatment, a CT scan was performed to evaluate response, finding a calcification of the mass without significant reduction of the overall size.
  • Because CT was inconclusive in the assessment of response to therapy, a 18F-FDG PET scan was performed.
  • The 18F-FDG PET scan did not show any pathological uptake in the mediastinum but revealed a splenic and bone marrow diffusely increased 18F-FDG uptake.
  • The differential diagnosis included a secondary effect induced by G-CSF therapy as one of the main possibilities, but other possibilities such as a malignant infiltration by lymphoma could not be discarded.
  • This study showed no pathological findings, with a normal 18F-FDG uptake in the spleen and bone marrow.
  • Thus, the benign and reactive nature of the splenic and bone marrow 18F-FDG increased uptake found in the previous study was confirmed.
  • We consider that the stimulating effect that G-CSF therapy has on the spleen and bone marrow must be taken into account when performing a 18F-FDG PET scan, as it can be an important source of false-positive results.
  • [MeSH-major] Bone Marrow / metabolism. Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18 / metabolism. Granulocyte Colony-Stimulating Factor / adverse effects. Radiopharmaceuticals / metabolism. Spleen / metabolism. Spleen / radionuclide imaging. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000944.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down






Advertisement